Medexus Pharmaceuticals Inc. Forecasted to Earn Q2 2025 Earnings of $0.11 Per Share (TSE:MDP)

Medexus Pharmaceuticals Inc. (TSE:MDPFree Report) – Equities researchers at Leede Financial issued their Q2 2025 earnings per share estimates for shares of Medexus Pharmaceuticals in a note issued to investors on Monday, September 30th. Leede Financial analyst D. Loe expects that the company will post earnings per share of $0.11 for the quarter. Leede Financial has a “Speculative Buy” rating and a $8.25 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at $0.34 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.23 EPS, Q1 2027 earnings at $0.11 EPS, Q2 2027 earnings at $0.12 EPS, FY2027 earnings at $0.56 EPS and FY2028 earnings at $0.79 EPS.

MDP has been the subject of several other research reports. Stifel Nicolaus increased their price objective on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, June 26th. Finally, Stifel Canada raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of C$5.25.

View Our Latest Research Report on Medexus Pharmaceuticals

Medexus Pharmaceuticals Trading Up 2.7 %

Medexus Pharmaceuticals stock opened at C$2.64 on Wednesday. The firm has a market cap of C$64.76 million, a P/E ratio of 51.40 and a beta of 1.95. Medexus Pharmaceuticals has a 1-year low of C$1.44 and a 1-year high of C$3.27. The firm has a 50-day moving average of C$2.47 and a 200-day moving average of C$2.00.

Medexus Pharmaceuticals (TSE:MDPGet Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported C$0.11 EPS for the quarter, beating analysts’ consensus estimates of C$0.04 by C$0.07. The company had revenue of C$37.33 million during the quarter, compared to analyst estimates of C$36.95 million. Medexus Pharmaceuticals had a net margin of 1.00% and a return on equity of 3.95%.

About Medexus Pharmaceuticals

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Further Reading

Earnings History and Estimates for Medexus Pharmaceuticals (TSE:MDP)

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.